Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial

Area of Science:

• Pediatric Critical Care Medicine
• Pharmacology
• Hemodynamics

Background:

• Vasopressin is a vasoactive agent explored for treating vasodilatory shock in pediatric patients.
• Current treatment guidelines for pediatric vasodilatory shock often involve catecholamines and other vasopressors.
• The efficacy and safety of vasopressin as an adjunctive therapy in this population require further investigation.

Purpose of the Study:

• To evaluate the efficacy and safety of low-dose vasopressin as an adjunctive agent in pediatric vasodilatory shock.
• To determine if vasopressin improves hemodynamic stability and reduces mortality in critically ill children.
• To assess secondary outcomes including organ failure and length of intensive care unit stay.

Main Methods:

• A multicenter, double-blind, randomized controlled trial was conducted.
• Children with vasodilatory shock received either low-dose vasopressin or placebo, alongside open-label vasoactive agents.
• The primary outcome was time to vasoactive-free hemodynamic stability; secondary outcomes included mortality and organ-failure-free days.

Main Results:

• No significant difference in time to hemodynamic stability was observed between the vasopressin and placebo groups (49.7 vs. 47.1 hours, P = 0.85).
• The vasopressin group showed a trend towards increased mortality (30% vs. 15.6%), though not statistically significant (RR 1.94, P = 0.24).
• There were no significant differences in organ-failure-free days, ventilator-free days, length of stay, or adverse event rates.

Conclusions:

• Low-dose vasopressin did not demonstrate beneficial effects in treating pediatric vasodilatory shock.
• A concerning, though not statistically significant, trend towards increased mortality was observed with vasopressin use.
• Further research may be needed to clarify the role, if any, of vasopressin in pediatric vasodilatory shock management.